Navigation Links
Sirion Therapeutics New Drug Application for Ganciclovir is Accepted for Review by the FDA for the Treatment of Ocular Herpes
Date:1/26/2009

valuable treatment option for U.S. clinicians who treat herpetic keratitis," noted Herb Kaufman, M.D., Sirion Ophthalmologist Emeritus and renowned herpetic keratitis researcher and clinician.

About Herpetic Keratitis

Herpes simplex virus (HSV) infections are very common, with nearly 60% of the U.S. population showing evidence of infection by age five. Approximately 1% of infected patients develop ocular outbreaks, with 20,000 primary cases of ocular herpes diagnosed in the U.S. each year.

After the primary infection, ocular HSV typically becomes latent until triggers such as stress, UV radiation, and hormonal changes reactivate the virus and cause recurrent outbreaks. Those recurrences account for an additional 28,000 cases per year in the U.S. The risk of blindness increases with the number and severity of recurrences, making prompt treatment imperative to limit scarring and other more serious complications caused by herpetic epithelial ulcers.

About Ganciclovir Ophthalmic Gel, 0.15%

Sirion Therapeutics has an exclusive licensing agreement with Laboratoires Thea of France for the U.S. rights to develop and market ganciclovir ophthalmic gel, 0.15%. Available in Europe under the brand name Virgan(R), this topical ophthalmic antiviral gel has successfully treated herpetic viral infections for more than 10 years.

In 2007, Sirion received orphan drug designation from the FDA for ganciclovir ophthalmic gel. This designation is a special status for diseases or conditions that affect fewer than 200,000 patients in the United States.

About Sirion Therapeutics, Inc.

Sirion Therapeutics is a privately held biopharmaceutical company pursuing the discovery, development, and commercialization of products addressing unmet medical needs in the protection and preservation of eyesight. Sirion's diverse product portfolio includes products that address
'/>"/>

SOURCE Sirion Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sirion Therapeutics Announces FDA Approval of Durezol(TM) for Treatment of Postoperative Ocular Inflammation and Pain
2. Sirion Therapeutics Preclinical Studies: Two New Potential Advances in Treatment of Retinal Diseases to be Presented at ARVO
3. Sirion Therapeutics Highlights Pivotal Trial Results of Durezol(TM) at the American Society of Cataract and Refractive Surgery Annual Symposium
4. Sirion Therapeutics Acquires Worldwide License to Develop New Treatment for Ocular Diseases
5. Sirion Therapeutics Supports Ophthalmic Education
6. Frost & Sullivan Recognizes ESBATechs Innovation in Developing Antibody Fragments for Biologic Therapeutics
7. Cell Therapeutics, Inc. (CTI) to Present at 11th Annual BIO CEO & Investor Conference
8. Cell Therapeutics, Inc. Provides Update on the Special Meeting of Shareholders
9. Nile Therapeutics Announces Focus on CD-NP for Acute Heart Failure and Termination of 2NTX-99 Program
10. Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009
11. Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for Alagebrium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014 Research and Markets ... Technology Market - Global Industry Analysis, Size, Share, Growth, ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... acids (either DNA or RNA) into cells. This technology ... cancer cells and protein metabolism by affecting the nuclear ...
(Date:7/11/2014)... July 11, 2014 Cayenne Medical, ... specializing in the soft tissue reconstruction segment, announced ... System for surgeries involving the shoulder and extremities. ... a novel, inserter-controlled deployment method. The unique delivery ... deployment, anchor pull-out, or anchor displacement (also commonly ...
(Date:7/10/2014)... July 10, 2014 Terascala, the industry ... that Alan Swahn, a former vice president of product ... as vice president of marketing. Terascala’s software when combined ... NetApp create the highest performance and most reliable solutions ... to guide Terascala’s channel expansion and broaden its product ...
(Date:7/10/2014)... Senior supply chain management executives from over ... challenges of “Reducing Cost, Lead Time, & Defects in ... Describing the partnership of the Bio Supply Management Alliance ... ( SCMI) of the University of San Diego ... Kroc Institute of Peace and Justice in San Diego, ...
Breaking Biology Technology:International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3Terascala Expands Executive Team 2Terascala Expands Executive Team 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4
... , Collaboration with Biomodels facilitates development ... Sept. 16 Avaxia Biologics, Inc., a biotechnology company developing oral ... that it has been awarded a Phase I SBIR grant from ... development of a novel antibody therapeutic for oral mucositis. , ...
... Sealers, cleaners, and ... , ... 16, 2009 - Tile Media Properties (TMP), best known for The Tile Doctor brand and ... The 10 year-old Atlanta-based company receives millions of unique visitors annually and is well-recognized as ...
... DIEGO, Sept. 16 Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX ), a ... will be speaking at the UBS Global Life Sciences Conference. The details ... September 22, 2009, Time: 2:30pm Eastern, ... Graham Cooper, Chief Financial Officer, , , ...
Cached Biology Technology:Avaxia Biologics Awarded Phase I SBIR Grant to Develop Antibody Therapeutic for Oral Mucositis 2Avaxia Biologics Awarded Phase I SBIR Grant to Develop Antibody Therapeutic for Oral Mucositis 3The Tile Doctor Launches Inaugural Product Line 2The Tile Doctor Launches Inaugural Product Line 3
(Date:7/11/2014)... burning in eastern New South Wales, Australia when NASA,s ... 03:35 UTC on July 11 (12:35 p.m. local time/11:35 ... eastern New South Wales (NSW), the Moderate Resolution Imaging ... the region and spotted smoke (light brown) from various ... are outlined in red. , The New South Wales, ...
(Date:7/11/2014)... scientists have set a "mouse TRAP" to capture the ... recent study published in the Journal of Clinical ... technique called TRAP to extract cellular and genetic information ... scientists at the Rockefeller Institute for Medical Research in ... protein-making machinery, or ribosomes, of the cell type of ...
(Date:7/11/2014)... team of researchers, including scientists from the Max Planck ... reported a major step in understanding photosynthesis, the process ... the oxygen in its atmosphere and which is therefore ... , The researchers report the first direct visualization ... the step in which a specific protein complex, photosystem ...
Breaking Biology News(10 mins):A first direct glimpse of photosynthesis in action 2
... common condition affecting 12-20 percent of Americans age 65 ... heart attack and strokeand many with the disease may ... Interventional Radiology. For more than a decade, the ... Life, has helped identify this very serious and potentially ...
... , This press release is available in German . ... as defined by the EU Water Framework Directive is unlikely to ... a study in which data from the four largest rivers in ... analysed over ten years. The study was carried out by the ...
... Agriculture (USDA) aerial photography survey of 38,000 wildfire-burned acres ... first evidence that the invasive leafy spurge weed is ... Booth, a rangeland specialist with the Agricultural Research Service ... the survey using a technique he developed called Very ...
Cached Biology News:Interventional radiologists: Learn about peripheral arterial disease and get moving 2Interventional radiologists: Learn about peripheral arterial disease and get moving 3Poor outlook for water quality in Germany 2Digital cameras open new view of America's West 2
... Green II RNA gel stain is ... has bright fluorescence when bound to RNA ... ideal for use with either formaldehyde/agarose or ... UV transilluminators. A 500 µL unit size ...
... SYBR Green II RNA gel stain ... has bright fluorescence when bound to RNA and ... use with either formaldehyde/agarose or polyacrylamide gels using ... stains 100 minigels. A 500 µL unit size ...
... EIA Principle: Glutathion-S-transferases (GST) ... are involved in the detoxification processes. ... subgroups: Alpha, Mu, Pi, Teta and ... physiochemical, immunological, enzymatic and s Sample ...
... Microarrays designed for RNA aptamer screening and ... and powerful Paraflo microfluidic on-chip synthesis platform. ... our comprehensive DNA/RNA Aptamer Microarray Service. ... RNA Aptamer Microarray contains greater than 1500 ...
Biology Products: